CRISPR Therapeutics AG (CRSP) Total Non-Current Liabilities (2015 - 2026)

CRISPR Therapeutics AG has disclosed Total Non-Current Liabilities across 12 years of filings, most recently posting $905.3 million for Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $905.3 million, up 171.36% year-over-year; the trailing twelve-month figure through Mar 2026 was $905.3 million (up 171.36% YoY), and the FY2025 annual result was $337.3 million, up 10.04% from the prior year.
• Total Non-Current Liabilities came in at $905.3 million for Q1 2026 at CRISPR Therapeutics AG, up from $337.3 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $905.3 million in Q1 2026 to a low of $306.5 million in Q4 2024.
• The 5-year median for Total Non-Current Liabilities is $353.6 million (2023), against an average of $380.9 million.
• Across the five-year window, Total Non-Current Liabilities declined 11.58% in 2025 and surged 171.36% in 2026, its largest moves.
• CRISPR Therapeutics AG's Total Non-Current Liabilities stood at $361.6 million in 2022, then declined by 4.37% to $345.8 million in 2023, then fell by 11.36% to $306.5 million in 2024, then climbed by 10.04% to $337.3 million in 2025, then surged by 168.41% to $905.3 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $905.3 million (Q1 2026), $337.3 million (Q4 2025), and $324.0 million (Q3 2025), per Business Quant data.